Press Releases - Archive



Shareholder Tools


 
Press Releases - Archive
Date Title and Summary View
Jun 11, 2015 SOUTH SAN FRANCISCO, Calif., June 11, 2015 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant (MDR) gram-negative infections, announced today the appointment of Mr. Greg Stea to its Board of Directors as a Class II director. In conjunction with t...
May 11, 2015 SOUTH SAN FRANCISCO, May 11, 2015 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant (MDR) gram-negative infections, today reported an update of its Phase 3 plazomicin clinical programs as well as financial results for the quarter ended March 31,...
May 5, 2015 SOUTH SAN FRANCISCO, Calif., May 5, 2015 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant (MDR) gram-negative infections, announced today that it will present at the Bank of America Merrill Lynch 2015 Health Care Conference in Las Vegas, Nevada...
Apr 30, 2015 SOUTH SAN FRANCISCO, Calif., April 30, 2015 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant (MDR) gram-negative infections, today announced it has reached a settlement of its claim with the Defense Threat Reduction Agency (DTRA), a division of...
Apr 9, 2015 SOUTH SAN FRANCISCO, Calif., April 9, 2015 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant (MDR) gram-negative infections, announced today that it will present at the 14th Annual Needham Healthcare Conference in New York, New York. Dr. Kenneth...
Mar 30, 2015 SOUTH SAN FRANCISCO, Calif., March 30, 2015 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant (MDR) gram-negative infections, is pleased to host a webcast and teleconference providing an update on its lead program, plazomicin. The webcast and te...
Mar 16, 2015 SOUTH SAN FRANCISCO, Calif., March 16, 2015 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant (MDR) gram-negative infections, today reported financial results for the quarter and year ended December 31, 2014. During the fourth quarter, the C...
Mar 12, 2015 SOUTH SAN FRANCISCO, Calif., March 12, 2015 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant (MDR) gram-negative infections, announced today that it will present at the Jefferies 2015 Antibiotic Summit in New York, New York. Kenneth Hillan, Chi...
Mar 12, 2015 SOUTH SAN FRANCISCO, Calif., March 12, 2015 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant (MDR) gram-negative infections, announced today the appointments of Dr. Alan Colowick and Dr. Kent Lieginger to its Board of Directors. In conjunction ...
Feb 25, 2015 SOUTH SAN FRANCISCO, Calif., Feb. 25, 2015 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant (MDR) gram-negative infections, announced today that it will present at the Cowen and Company 35th Annual Health Care Conference in Boston, Massachusett...
Page: FirstPrevious ...
12
... NextLast
= add release to Briefcase